- The drug, daraxonrasib, has shown the potential to nearly double the survival time for patients with advanced pancreatic cancer.
- Pancreatic cancer is often diagnosed at advanced stages, with over 90 per cent of patients having KRAS genetic mutations previously considered untreatable.
- An early-phase clinical trial involving 38 patients found that daraxonrasib increased overall survival to 15.6 months, compared to 6.7 months with standard chemotherapy.
- The drug, a RAS inhibitor, targets mutated KRAS genes, which are frequently found in pancreatic, lung, and colorectal cancers, putting them into a dormant state.
- Researchers believe daraxonrasib could represent a significant advancement in treating pancreatic cancer, with further, larger clinical trials currently underway.
IN FULL
